Advertisement
ADVANCED SEARCH

This Article Figures Only Full Text Full Text (PDF) Résumé Online Appendices Correction (v180,p1038) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huss, A. Articles by Egger, M. Search for Related Content PubMed PubMed Citation Articles by Huss, A., PhD Articles by Egger, M., MD MSc Related Collections Drugs: immunological products and vaccines Vaccination Other respiratory infections Related Articles

Efficacy of pneumococcal vaccination in adults: a meta-analysis

From the Institute of Social and Preventive Medicine (Huss, Scott, Egger), University of Bern, Bern, Switzerland; the Department of Geriatrics (Stuck), Inselspital University Hospital, Bern, Switzerland; the University Department of Geriatrics (Stuck), Spital Netz Bern Ziegler, Bern, Switzerland; and the Department of Social Medicine (Trotter, Egger), University of Bristol, Bristol, UK

Correspondence to: Dr. Matthias Egger, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland; fax 41 31 631 35 20; egger{at}ispm.unibe.ch

Background: Clinical trials and meta-analyses have produced conflicting results of the efficacy of unconjugated pneumococcal polysaccharide vaccine in adults. We sought to evaluate the vaccine's efficacy on clinical outcomes as well as the methodologic quality of the trials.

Methods: We searched several databases and all bibliographies of reviews and meta-analyses for clinical trials that compared pneumococcal polysaccharide vaccine with a control. We examined rates of pneumonia and death, taking the methodologic quality of the trials into consideration.

Results: We included 22 trials involving 101 507 participants: 11 trials reported on presumptive pneumococcal pneumonia, 19 on all-cause pneumonia and 12 on all-cause mortality. The current 23-valent vaccine was used in 8 trials. The relative risk (RR) was 0.64 (95% confidence interval [CI] 0.43–0.96) for presumptive pneumococcal pneumonia and 0.73 (95% CI 0.56–0.94) for all-cause pneumonia. There was significant heterogeneity between the trials reporting on presumptive pneumonia (I² = 74%, p < 0.001) and between those reporting on all-cause pneumonia (I² = 90%, p < 0.001). The RR for all-cause mortality was 0.97 (95% CI 0.87–1.09), with moderate heterogeneity between trials (I² = 44%, p = 0.053). Trial quality, especially regarding double blinding, explained a substantial proportion of the heterogeneity in the trials reporting on presumptive pneumonia and all-cause pneumonia. There was little evidence of vaccine protection in trials of higher methodologic quality (RR 1.20, 95% CI 0.75–1.92, for presumptive pneumonia; and 1.19, 95% CI 0.95–1.49, for all-cause pneumonia in double-blind trials; p for heterogeneity > 0.05). The results for all-cause mortality in double-blind trials were similar to those in all trials combined. There was little evidence of vaccine protection among elderly patients or adults with chronic illness in analyses of all trials (RR 1.04, 95% CI 0.78–1.38, for presumptive pneumococcal pneumonia; 0.89, 95% CI 0.69–1.14, for all-cause pneumonia; and 1.00, 95% CI 0.87–1.14, for all-cause mortality).

Interpretation: Pneumococcal vaccination does not appear to be effective in preventing pneumonia, even in populations for whom the vaccine is currently recommended.

This article has been cited by other articles:

				B. T. Korber, N. L. Letvin, and B. F. Haynes T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces J. Virol., September 1, 2009; 83(17): 8300 - 8314. [Full Text] [PDF]

				R. M. Andrews and S. A. Moberley Efficacy of pneumococcal polysaccharide vaccine Can. Med. Assoc. J., May 26, 2009; 180(11): 1135 - 1135. [Full Text] [PDF]

				P. Scott, A. Huss, A. E. Stuck, C. Trotter, and M. Egger Efficacy of pneumococcal polysaccharide vaccine Can. Med. Assoc. J., May 26, 2009; 180(11): 1134 - 1135. [Full Text] [PDF]

				Pneumococcal Polysaccharide Vaccine: Efficacy Remains Controversial Journal Watch (General), January 27, 2009; 2009(127): 1 - 1. [Full Text]

				R. Andrews PhD MPH and S. A. Moberley BN MPH The controversy over the efficacy of pneumococcal vaccine Can. Med. Assoc. J., January 6, 2009; 180(1): 18 - 19. [Full Text] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2009, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.